PharmaTelevision - Tim Sparey, Head of Business Development talks about Proximagen’s partnering strategy.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Tim Sparey, Head of Business Development talks about Proximagen’s partnering strategy.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tim Sparey, Head of Business Development at Proximagen

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Recent deals

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at Bio-Europe in Milan, Spring 2011. On this show I have Tim Sparey, who is Head of Business Development at a company called Proximagen based in the UK, welcome.

Tim Sparey:

Thank you.

Fintan Walton:

Proximagen, is a company that's floated on the market on the AIM market, it has its history goes back to King's College in London, tell us a little bit about that history?

Tim Sparey:

The company was founded around 2003- 2004 and the time the main focus was on Parkinson's disease . The academic founder was Professor Peter Jenner and he had at that time and indeed still has world leading expertise in Parkinson's particularly preclinical and so the company for the first four or five-years had a main focus on the early stage research on Parkinson's disease and then since then progressed the development interest in other diseases of the CNS particularly in neurology and expanded it's focus, but those certainly where the early interests and we still retain interest in Parkinson's disease ?

Fintan Walton:

Right, and part of that journey has also been the acquisition of products as well and companies, tell us about the recent deals that you've done?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Tim Sparey

Head of Business Development

Dr. Tim Sparey , currently serves as Head of Business Development at Proximagen.Tim joined Proximagen in November 2009 from Merck-Serono where he held the role of Head of UK Business Development. Formerly he was a Director in Licensing & External Research, Europe at Merck and he was also a Research fellow in the Department of Medicinal Chemistry (Group Leader) at Merck, working in Alzheimer's disease, Schizophrenia, Parkinson's disease, anaesthetics and stem cell therapeutics.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Proximagen

Proximagen Group plc (AIM:PRX) is focused on the development and commercialization of novel therapeutics for diseases of the CNS, neuroinflammation/inflammation and oncology. Proximagen Group plc are developing a broad pipeline of drug candidate programmes and have plans for substantial future growth through a strategy of acquisition and consolidation of innovative drug candidate programmes in diseases of the CNS, neuroinflammation/inflammation and oncology. The Company's strong balance sheet makes us one of the best capitalized biotechnology companies in the small and mid cap European biotech sector.